You searched for non small cell lung cancer

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

News remove

Older than 2 years remove

Home remove

Your search for non small cell lung cancer returned 129 results

Sort Results:

Relevant Recent

News

Combined Modalities Improve Survival in Stage III Inoperable NSCLC

January 21, 2021

This study tested the efficacy of singular and combined treatment modalities on survival in patients with inoperable, locally advanced non-small cell lung cancer (≥70 years).

News

Lorlatinib Superior to Crizotinib for ALK-Positive NSCLC

November 23, 2020

Interim analysis shows risk for disease progression or death lower for first-line therapy with lorlatinib versus crizotinib

News

Atezolizumab Prolongs Survival in NSCLC With PD-L1 Expression

October 2, 2020

Overall survival longer than for chemotherapy in metastatic NSCLC with high PD-L1 expression.

News

BMI, Survival Linked in NSCLC Treated With Atezolizumab

December 27, 2019

Overall, progression-free survival improved for patients with high BMI; link strongest with high PD-L1 expression

News

First-Line Osimertinib May Up Survival in EGFR-Mutated NSCLC

December 6, 2019

For previously untreated disease, overall survival longer with osimertinib versus comparator EGFR-TKIs

News

Many Not Receiving Guideline-Concordant Tx for Lung Cancer

November 4, 2019

Elderly, non-Hispanic blacks particularly less likely to receive recommended lung cancer treatment.

News

Electronic Nose Analysis May Predict Response to Anti-PD-1 Therapy in NSCLC

September 19, 2019

Initial breath analysis predicts individual treatment response to anti-PD-1 therapy at three months

News

Adding Bevacizumab May Improve Overall Survival in NSCLC

June 19, 2019

Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non-small cell lung cancer

News

Durvalumab Extends Survival vs Placebo in Stage 3 Non-Small Cell Lung CA

October 29, 2018

Overall survival was significantly prolonged with durvalumab versus placebo (stratified hazard ratio [HR] for death, 0.68; P=.0025). For progression-free survival, the median duration was 17.2 months in the durvalumab group and 5.6 months in the placebo group.

ACR/ARHP 2018 Annual Meeting

Biologic DMARD Treatment Linked to Weight Gain in Inflammatory Arthritis

October 23, 2018

Small but significant increases in weight (0.02lb) and BMI (0.006 lbl P<.001 for both) were observed over time. Moreover, a negative association between DAS28 and increased weight (-0.56) as well as BMI (-0.08; P<.001 for both) was reported, implying that an increase in weight was linked to lower disease activity.